Lightening the Lupus Load
- … show all 0 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Systemic lupus erythematosus (SLE) is an autoimmune disorder that mainly affects women and is characterized by chronic inflammation. A range of clinical symptoms is associated with SLE, some life-threatening and all of which substantially reduce quality of life. Although management of SLE has improved over the past few decades, this is not due to improved pharmacotherapy as no new drugs for SLE have been approved by the US FDA in over 30 years. Indeed, an unmet need for safer and more effective therapies than the anti-inflammatories and immunosuppressants currently employed is driving new drug development.
Most clinical investigations are focused on targeting specific immune-mediated pathways important in pathogenesis of SLE. Compounds targeting B cells are popular, with pivotal phase III clinical trials ongoing of Rituxan® (rituximab) from Genentech and Roche, epratazumab from Immunomedics and Riquent® (abetimus) from La Jolla Pharmaceutical. CellCept® (mycophenolate m
- Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353 (21): 2219–28 CrossRef
- Garcia BA, Busby SA, Shabanowitz J, et al. Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition. J Proteome Res 2005; ASAP Web Release Date: 5 Nov 2005